npj Precision Oncology (May 2024)

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

  • Zi-Jing Li,
  • William Pat Fong,
  • Dong-Sheng Zhang,
  • Hui-Yan Luo,
  • Dong-Liang Chen,
  • Yan-Yu Cai,
  • Zhi-Gang Chen,
  • Jian-Li Duan,
  • Zi-Yao Huang,
  • Yu-Ting Lu,
  • Xiao-Xia Huang,
  • Yu-Hong Li,
  • De-Shen Wang

DOI
https://doi.org/10.1038/s41698-024-00598-7
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi) in CRC remain undetermined. Herein, we examined a series of ALK-positive CRC patients who underwent various lines of ALKi treatment. Notably, we detected an ALK 1196M resistance mutation in a CRC patient who received multiple lines of chemotherapy and ALKi treatment. Importantly, we found that Brigatinib and Lorlatinib demonstrated some efficacy in managing this patient, although the observed effectiveness was not as pronounced as in non-small cell lung cancer cases. Furthermore, based on our preliminary analyses, we surmise that ALK-positive CRC patients are likely to exhibit inner resistance to Cetuximab. Taken together, our findings have important implications for the treatment of ALK-positive CRC patients.